Headway, the company building a new mental healthcare system, announced its participation in the Aligned Innovation initiative, a groundbreaking cross-indu...
bluebird bio, Inc. (Nasdaq: BLUE) announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority...
At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete Genomics, a pioneering genomic sequencing company, will highligh...
Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) announced that Syndax has entered into a $350 million synth...
OmniActive Health Technologies (OmniActive) announced the acquisition of ENovate Biolife (ENovate), further strengthening its commitment to innovative...
QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth ...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripot...
November is Lung Cancer Awareness Month, and the American Lung Association (Lung Association) is kicking it off by offering free lung cancer screenings to&...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported its consolidated financial results for the third quarter...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that a detailed analysis of the positive Phase III INAVO120 results, evaluat...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced new late-breaking data on its Elecsys Amyloid Plasma Panel (combination of pTau181 and ApoE4), for Alzhei...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates announced a significant expansion in their quality control (QC) test...
© 2025 Biopharma Boardroom. All Rights Reserved.
